Castle Biosciences, Inc. (CSTL)

NASDAQ: CSTL · IEX Real-Time Price · USD
25.09
+0.59 (2.39%)
At close: Feb 27, 2024, 4:00 PM
25.00
-0.09 (-0.36%)
After-hours: Feb 27, 2024, 7:52 PM EST
2.39%
Market Cap 659.44M
Revenue (ttm) 192.01M
Net Income (ttm) -75.50M
Shares Out 26.91M
EPS (ttm) -2.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 278,206
Open 24.75
Previous Close 24.51
Day's Range 24.37 - 25.60
52-Week Range 9.26 - 26.70
Beta 0.97
Analysts Strong Buy
Price Target 32.00 (+27.54%)
Earnings Date Feb 28, 2024

About CSTL

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an indiv... [Read more]

Sector Healthcare
IPO Date Jul 25, 2019
Employees 587
Stock Exchange NASDAQ
Ticker Symbol CSTL
Full Company Profile

Financial Performance

In 2022, CSTL's revenue was $137.04 million, an increase of 45.65% compared to the previous year's $94.09 million. Losses were -$67.14 million, 114.6% more than in 2021.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is $32.0, which is an increase of 27.54% from the latest price.

Price Target
$32.0
(27.54% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AJCC8--Castle announced a study showing DecisionDx-Melanoma provided significantly better risk stratification than AJCC8 staging in stage I melanoma.

1 day ago - Business Wire

Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences today announced it will release its financial results for Q4 & year ended Dec. 31, 2023 after the close of market o...

20 days ago - Business Wire

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences' DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--New study finds using Castle's DecisionDx-SCC test to guide ART decisions for SCC patients could result in substantial Medicare healthcare savings.

5 weeks ago - Business Wire

Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present new data across its dermatologic portfolio of GEP tests at the 2024 Winter Clinical Dermatology Conference - Hawaii.

6 weeks ago - Business Wire

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary...

7 weeks ago - Business Wire

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4).

2 months ago - Business Wire

Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of a new study that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma.

3 months ago - Business Wire

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle announced that data spanning its dermatologic portfolio of GEP tests was recently presented at the 2023 ASDS Annual Meeting.

3 months ago - Business Wire

Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences has been named a Houston Chronicle Top Workplace for the third year in a row.

3 months ago - Business Wire

Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announces data demonstrating the impact of IDgenetix® on medication response/remission rates in patients with major depressive ...

3 months ago - Business Wire

Castle Biosciences to Present at Upcoming Investor Conferences

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at three investor conferences later this month.

3 months ago - Business Wire

Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced data from an exploratory study investigating the potential for developing a test that would complement DecisionDx®-UM.

4 months ago - Business Wire

Early Discovery Data Shows Ability of Castle Biosciences' Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data related to its inflammatory skin disease pipeline program.

4 months ago - Business Wire

Castle Biosciences Reports Third Quarter 2023 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle today announced its financial results for the third quarter and nine months ended September 30, 2023.

4 months ago - Business Wire

Castle Biosciences to Present New Data on its TissueCypher® Barrett's Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Barrettsesophagus--Castle will highlight the risk stratification provided by its TissueCypher® Barrett's Esophagus test through two posters at ACG 2023.

4 months ago - Business Wire

Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the third quarter ended Sept. 30, 2023, after the close of market on Thursday, Nov. 2, 2...

4 months ago - Business Wire

New Data Highlights Clinical Utility and Performance of Castle Biosciences' Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle will share new data across its dermatologic portfolio of gene expression profile (GEP) tests at the 2023 Fall Clinical Dermato...

4 months ago - Business Wire

DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced a new study demonstrating DecisionDx®-Melanoma outperforms the MSKCC nomogram in identifying patients at low risk of SLN positivit...

5 months ago - Business Wire

Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASTRO23--Castle will share new data on its DecisionDx®-SCC test at the American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting.

5 months ago - Business Wire

Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Barrettsesophagus--New data shows the ability of TissueCypher® test results to inform clinical decision-making in patients with non-dysplastic Barrett's ...

5 months ago - Business Wire

Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will ring the Nasdaq closing bell on Wednesday, Sept. 27, 2023, to raise awareness of melanoma in honor of patients impacted by the disease.

5 months ago - Business Wire

Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--National award recognizes Castle's strong culture and employee engagement.

5 months ago - Business Wire

TissueCypher® Barrett's Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett's Esophagus

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AI--Study shows TissueCypher outperformed pathology review in predicting progression to high-grade dysplasia or esophageal cancer in Barrett's patients.

5 months ago - Business Wire

Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences has received its Clinical Laboratory Permit from the New York State Department of Health for its laboratory in Pittsburgh.

6 months ago - Business Wire

Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences' IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced data from a study of its IDgenetix® test that was recently shared at Psych Congress 2023.

6 months ago - Business Wire